Akari Therapeutics plc — 2015 Q1 filing summary
Entity note: The supplied filing is for Celsus Therapeutics plc, not Akari Therapeutics plc. The filing itself does not explain the difference from the request metadata. It covers the unaudited quarter ended March 31, 2015; financial statement amounts are in U.S. dollars, generally thousands.
Business context and key financials
Celsus was a development-stage biopharmaceutical company with no product revenue. After its lead MRX-6 cream Phase II trial failed to meet the primary endpoint, the company suspended development and began evaluating strategic alternatives.
| Metric | Q1 2015 | Q1 2014 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $1.551 million | $0.800 million; up 94% |
| General and administrative expense | $0.791 million | $1.083 million; down 27% |
| Operating loss | $2.342 million | $1.883 million |
| Net loss | $2.317 million | $1.740 million |
| Net loss per share | $0.04 | $0.04 |
| Cash used in operations | $2.200 million | $2.048 million |
| Cash and cash equivalents, March 31 | $4.016 million | $6.216 million at December 31, 2014 |
No revenue or profit margins were reported. At March 31, current assets were $4.273 million and current liabilities $0.910 million. The balance sheet reported $0.812 million in long-term liabilities, including a $0.774 million liability for options and warrants; the filing does not show conventional borrowings. Accumulated deficit was $32.507 million. Outstanding ordinary shares were 55,636,283.
Changes, outlook, and risks
- R&D expense rose primarily because of increased formulation, synthesis, manufacturing, and clinical-trial costs. G&A declined mainly with lower legal, consulting, professional, accounting, and share-based compensation costs.
- Financial results included $0.535 million of net financial expense, primarily associated with revaluation of warrant liabilities. The reported $0.560 million tax benefit arose from surrendering eligible U.K. R&D-related trading losses.
- Following the unsuccessful MRX-6 trial, Celsus suspended clinical and preclinical development, pursued cost and staff reductions, and considered business alternatives, including a merger, asset transaction, or liquidation. It sent the FDA a letter on April 6, 2015 to close the MRX-6 IND.
- Management said cash was expected to fund reduced operations for the next 12 months, assuming no business-alternative transaction is completed. This estimate depends on cost reductions and program suspensions. The company anticipated needing additional financing for longer-term plans and had no committed additional capital; financing availability and terms were uncertain.
- Office lease commitments totaled $1.383 million through August 2019. Management said it might sublease some space. There were no material legal proceedings or off-balance-sheet arrangements disclosed.
- Key risks include failure to secure a transaction or financing, possible liquidation, further shareholder dilution, and the suspended development programs. On April 9, 2015, the company received notice that its ADS bid price was below Nasdaq’s $1.00 minimum; the compliance period ran through October 6, 2015.
Important facts for investors to verify
- Confirm the issuer identity and its relationship, if any, to Akari Therapeutics; this filing identifies Celsus Therapeutics plc.
- Check subsequent disclosures for the outcome of strategic-alternative discussions, any financing or transaction, and whether liquidation was pursued.
- Verify actual cash burn and runway after restructuring against management’s conditional 12-month estimate.
- Review Nasdaq bid-price compliance developments and any share-ratio changes or equity issuance.
- Assess the effect of warrant and option terms, including anti-dilution provisions, on future liabilities and potential dilution.